The Global Immunization Vision and Strategy (GIVS), 2006-2015 [1] , was endorsed by the 58th World Health Assembly (recommendation WHA58.15) as well as the 2005 United Nations Children's Fund (UNICEF) Executive Board [2] . Among the recommendations of GIVS are the use of a combination of approaches to reach those who are eligible for immunization, ensure that unreached persons are reached in every district $4 times a year, assess and develop appropriate interventions for integration, and provide access to immunization services in complex humanitarian emergencies.
Following the GIVS recommendations, countries use a strategy known as Child Health Days (CHDs) to deliver multiple maternal and child health interventions annually or biannually. CHDs are usually time-limited activities that last for 1-8 weeks; in the case of immunizations, CHDs target a wider age cohort than routine programs. They share many similarities with mass immunization campaigns, which are also considered supplementary to the routine healthcare system and are meant to extend coverage to areas and populations underserved by routine services and achieve high coverage of selected interventions rapidly. In many countries, CHDs build on an existing immunization campaign infrastructure and serve to deliver a broader package of interventions [3] . In sub-Saharan Africa, CHDs have been used both in countries with weak infrastructure and in countries with stronger routine service delivery systems in place [3] .
There are a number of potential benefits to using the CHD integrated delivery strategy: the rapid increase in coverage for several interventions at a time, improved equity of service delivery, and resource savings [3] [4] [5] . However, there are concerns that CHDs may not be cost-effective and sustainable. There is also the risk of delivering too many interventions at the same time, which may jeopardize quality of service and coverage [5, 6] . In addition, there are questions regarding how the CHDs interact with the routine health system and their impact on overall disease incidence [3, 6] . However, in areas where the healthcare system and other infrastructure are weak, use of the CHD strategy may help to overcome barriers to access of key maternal and child health interventions, including transportation difficulties, resource availability, and community awareness. In some cases, CHDs may be the only method to provide key child survival interventions on a routine basis [5] .
SOMALIA CONTEXT
Somalia has been without a central government since a military coup in 1991. Years of civil war followed, which has devastated much of the country's infrastructure, including its healthcare system [7] . Multiple attempts to restore the government since 1991 have been unsuccessful, and Somalia remains in conflict, with a large population of internally displaced persons with inadequate access to health and social services [8] . Indicators of the collapse of the health system include child and maternal mortality rates being among the highest globally [9] and record low levels of routine infant immunization coverage for all antigens, which have remained at these levels for the past 20 years [10] . Somalia's routine immunization services, which are heavily supported by UNICEF and partner agencies, use both fixed health facilities and outreach into communities to deliver vaccination. However, security problems and inadequate resources hamper coverage of these services. To overcome the barrier of a collapsed primary healthcare system, Somalia's national immunization program has used a population-based campaign approach to conduct multiple supplemental immunization activities (SIAs) to deliver polio vaccine. The polio SIAs use an extensive network of polio staff, present in all districts of Somalia, who deliver vaccine at the household level. These SIAs are supported by the Polio Eradication Initiative under the leadership of the World Health Organization (WHO). In addition, between 2005 and 2009, 6 national and subnational measles SIAs reached coverage ranging from 73% to 89% of their target populations (children aged 9-59 months in 3 SIAs and children aged 9 months to 15 years in 3 additional SIAs) [11] . The polio SIAs have helped Somalia remain polio free since 2007, and the measles SIAs decreased reported measles cases from 12 000 in 2004 to 1081 in 2008, in spite of a weak routine immunization program [12] .
The achievements of polio and measles SIAs in Somalia prompted key stakeholders, including WHO and UNICEF, to consider a population-based campaign approach as a viable strategy for delivering multiple child and maternal health interventions. This evolved into Somalia's first CHDs, which would use the network of polio staff to deliver additional interventions at the community level.
The CHD intervention package (Table 1 ) was designed around recent evidence and recommendations on available child survival interventions [13] . The first CHD round was implemented from December 2008 to May 2009; the second CHD round was from August 2009 to April 2010 and was implemented as a rolling activity across the country. Both were supported by WHO and UNICEF.
To date only 2 published studies [5, 14] address CHD costs in any country. Consequently, little is known about their costeffectiveness, particularly in conflict-affected areas with limited means to routinely deliver health services. The objective of this study is to estimate the incremental costs, impact, costeffectiveness, and return on investment of the 2 rounds of CHDs that were conducted in Somalia, from the perspective of the donor.
DATA AND METHODS
Oral polio vaccine (OPV), measles vaccine, diphtheriatetanus-pertussis (DTP) vaccine, deworming tablets, oral rehydration salts (ORS), tetanus-toxoid (TT) vaccine, water treatment tablets (Aquatabs), Vitamin A, and measurement of mid upper-arm circumference (MUAC) comprised the package delivered during both rounds of CHDs, targeting children and women of childbearing age ( Table 1 ). The size of the targeted population of beneficiaries corresponds to WHO and UNICEF estimates used during the planning phase of the CHDs. However, the security situation rendered Lower Shabelle region inaccessible during both rounds and Benadir region inaccessible during the second round. For this reason, we calculated a second denominator figure consisting of the population living in the areas that could be reached (accessible beneficiaries) ( Table 1) .
The costs for each intervention were calculated as the cost of the commodity (eg, vaccine, sachets of ORS) plus a share of the total operational costs, which included transportation, logistics, stakeholder meetings, social mobilization, training and implementation, injection safety, field supervision, and monitoring but did not include salary costs incurred by UNICEF, WHO, and other implementing agencies. The unit costs of the commodities delivered during both rounds of CHDs varied from $0. Table 2) . The operational costs, obtained from the 2 implementing agencies, were distributed equally across the population that was targeted or accessible by the 9 interventions, such that an equal fraction of the costs was attributed to each targeted or accessible beneficiary per intervention. The reported total costs were $8.23 million for each round, for a total of $16.47 million for both rounds of CHDs combined; 38% for supplies and 62% for operational costs. In addition, we also estimate the economies of scale and scope of the 2 rounds of CHDs. ''Economies of scale'' refers to the reduction in the average costs resulting from a larger targeted or accessible population, whereas ''economies of scope'' refers to the reduction in average costs resulting from delivery of multiple interventions using the same delivery mode.
In the cost-effectiveness analyses, the added costs and health outcomes associated with an intervention are used to calculate the incremental cost-effectiveness ratio relative to some comparator. The health outcome for purposes of our analysis was mortality of children ,5 years old; the Lives Saved Tool (LiST) [15, 16] was used to model the incremental reduction in child deaths in 2009 and 2010 compared with a 2008 baseline. This tool, which was developed by a consortium of academic and international organizations, is based on work of the Child Health Epidemiology Reference Group (CHERG), which estimates country-specific mortality rates and distribution of the main causes of death for those ,5 years old, the proportion of these deaths that can be averted by specific interventions (affected fraction), and the estimated efficacy/effectiveness of child survival interventions [17] . The LiST model and assumptions are described in detail in a series of papers [18] . In Somalia, .75% of deaths among children 1-59 months of age are estimated to be caused by diarrhea, pneumonia, measles, and malaria [19] . [20] for Somalia. Administrative coverage estimates reported for the 2 rounds of CHDs (Table 3) were used as inputs into the model for the years 2009 and 2010. The estimates of lives saved by the CHDs are incremental to the impact of the routine healthcare delivery system. In addition to calculating lives saved, we calculated estimates of life years saved using the average life expectancy of 50 years for Somalia [9] and assumed the average age of each child saved by the CHDs to be 2 years. Although parts of the country were inaccessible for both rounds of CHDs, for the purpose of modeling impact, we assumed the coverage estimates to be homogeneous for the entire country in order to provide conservative estimates of impact. The impact evaluation was limited to OPV, measles vaccine, TT vaccine, DPT vaccine, and vitamin A and did not include deworming tablets, ORS, Aquatabs, or MUAC because the impact of these interventions on child mortality is difficult to estimate without additional assumptions regarding their use. ORS and Aquatabs were intended for use in the future in the event a child has an episode of diarrhea; each water treatment tablet could treat 20-25 L of raw water, with the treated water used to prepare ORS for the child. Results of MUAC screening were used to refer acutely malnourished children to selective feeding programs.
The estimates of costs and impact were used to compute the cost-effectiveness ratio. Results of cost-effectiveness analysis are typically expressed as cost per disability-adjusted life year (DALY)
However, because our analysis did not estimate the impact of CHDs on disability, we express our results as cost per years of life lost averted (or life years saved), which we consider equivalent to DALYs averted for the current analysis. The return on investment is a measure derived from the cost-effectiveness ratio, expressed as units of health outcome for a given amount of money invested in an intervention. In our analysis, we estimated the return on every $1 million invested in the 2 rounds of CHDs in Somalia.
Sensitivity analysis involves changing the parameters employed in an evaluation and studying how these changes affect the outcome. In addition to the base case scenario described above, we performed sensitivity analysis by varying the reported administrative coverage of the CHD interventions by 10 percentage points and estimating the impact, cost-effectiveness, and return on investment using the revised parameters. Because the analytic horizon for this analysis was only 2 years, we report undiscounted estimates for all scenarios. In addition to the sensitivity analysis, we also provide estimates for a what-if scenario assuming the use of single-dose pentavalent vaccine (procured at the prevailing UNICEF cost of $2.95/dose) instead of DTP vaccine. The pentavalent vaccine combines 5 vaccines in 1 injection to protect against 5 diseases: Haemophilus influenzae type B (Hib) disease, diphtheria, pertussis, tetanus, and hepatitis B (HepB).
RESULTS

Base Case
The estimated incremental costs, impact, cost-effectiveness, and return on investment in the 2 rounds of CHDs varied by round ( Table 4 ). The cost of the first round was an estimated $0.64 per targeted beneficiary with each intervention, with the second round cost marginally less at $0.62, for an average of $0.63 for both rounds combined. For example, at an average cost of $0.63 per intervention, the cost of delivering all 9 interventions to an eligible child was $5.67. The costs per accessible beneficiary were $0.84 in round 1 and $0.71 in round 2 (average of $0.77 for both rounds combined). If only OPV and vitamin A were delivered during both rounds of CHDs, as had been the case before 2009, and the operational costs remained unchanged, the per intervention average cost per targeted beneficiary would have been $1.69 (round 2, $1.67; round 1, $1.71) and the average cost per accessible beneficiary $1.84 (round 2, $1.83; round 1, $1.86).
Estimates from the LiST model indicate that round 1 of the CHD saved 4000 children's lives and round 2 saved 6000 children's lives (Table 4) . Measles vaccination and vitamin A supplementation accounted for nearly 85% of the estimated lives saved by the interventions delivered during the 2 CHD rounds. These estimates translate to a total of nearly 500 000 life years saved by both rounds of CHDs combined (Table 4) . The cost-effectiveness ratios were $44.00/life year saved by round 1, $28.00/life year saved by round 2, and $34.00/life year saved by both rounds combined. For every $1 million invested in the 2 rounds of CHDs, an estimated 615 children's lives (range, 473-756) and 29 500 life years (range, 22 700-36 300) were saved (Table 4) .
Sensitivity and Scenario Analysis
The impact estimates from the LiST are driven by the estimates of reported coverage for the interventions delivered during the CHDs. To test the robustness of these results, 10 percentage points were alternately subtracted from, and added to, the reported administrative coverage estimates and the resulting output reported as lower-bound and upper-bound estimates, respectively ( Table 5 ). The number of lives saved varied from 8000 to 13 000 for both rounds of CHDs combined, and the number of life years saved from 384 000 to 633 000 (Table 5 ). The cost-effectiveness ratios ranged from $26.00 to $43.00, and every $1 million invested in the campaigns saved between 485 and 800 lives and between 23 300 and 38 400 life years (Table 5) .
If the 2 rounds of CHDs had included the pentavalent vaccine in place of the DPT vaccine and the operational costs remained unchanged, this vaccine would have added $2 million to the costs but could have saved at least an additional 5000 lives over the course of 2 years, yielding a lower cost-effectiveness ratio of $24.00/life year saved (range, $20.00-$31.00). For every $1 million invested under this scenario, up to 952 children's lives (range, 761-1142) and 45 700 life years (range, 36 500-54 800) could have been saved.
DISCUSSION
To our knowledge, this study provides the first economic evaluation of the CHD strategy in a conflict-affected area. If the required data were collected in a systematic manner, similar analyses could be undertaken in other countries that are implementing a CHD strategy. Minimum data elements required for an economic evaluation include expenditure data disaggregated by commodities and operational costs, unit costs for each intervention, target population and population reached by each intervention, and estimates of baseline coverage.
Our data showed that costs per beneficiary were higher when only part of the population was reached because a number of the costs are fixed. In addition, compared with the delivery of OPV and vitamin A alone, the multiple interventions delivered using the same delivery mode resulted in lower average costs per intervention. These results thus demonstrate both economies of scale and scope.
The higher average cost per intervention per accessible beneficiary versus targeted beneficiary holds lessons for planning and budgeting in conflict settings. Although the intent during the planning phase may be to reach the country's entire population, the evolving security situation in Somalia dictated scaled back implementation, which resulted in higher average costs. With a larger accessible population for the second round of CHDs in Somalia, the average cost per intervention beneficiary declined by 18% ($0.63, down from $0.77 in the first round).
The nationwide administrative coverage reported for the first round of CHDs was lower because of the smaller accessible population. As a result, fewer deaths were estimated to have been averted by the first round than by the second round. Nonetheless, the estimated cost-effectiveness ratio of $34.00/life year saved compared with the $140.00 gross national income per capita for Somalia [9] meets the established guidelines for a very costeffective intervention [21] and also compares very favorably with other health sector ''best buys'' in sub-Saharan Africa [22] .
Our calculated values may represent an overestimate or an underestimate of the true cost-effectiveness ratio. First, we used administrative data for coverage, which often produce higher values than population-based surveys and could have resulted in artificially high cost-effectiveness ratios. However, our sensitivity analysis, in which we decreased the coverage estimates by Additionally, the operational costs of the CHDs were spread across only the modeled interventions for the calculation of costeffectiveness ratios. Finally, our analytic horizon of 2 years for the impact evaluation was very conservative, because the benefits of the interventions are likely to continue for several years into the future. A major question is whether additional interventions could be delivered through CHDs in Somalia. Because malaria is the fifth leading cause of death in children ,5 years old in Somalia [21] , insecticide-treated bed nets could be worth including in the package of interventions delivered during the CHDs. However, benefits would need to be calculated against the additional logistical costs, such as transportation and storage, and security and safety issues that result from the potential resale value of bed nets. A second consideration would be the substitution of DTP with pentavalent (DTP-HepB-Hib) vaccine, which offers the potential to further reduce child mortality and is expected to prevent adult deaths from hepatitis B virus-related cirrhosis and liver cancer; 10-dose vials of DTP-HepB-Hib vaccine, which have nearly the same cold chain requirement as conventional DTP (and consequently negligible additional cold chain costs), were prequalified by the WHO in August 2011. In addition, in countries such as Somalia, where contacts with the healthcare delivery system are rare and there is essentially no functioning routine immunization program, it may be worth performing an analysis of the additional lives that might be saved by the administration of pneumococcal and rotavirus vaccines during a CHD. As of 2008, 40% of deaths among Somali children 0-59 months of age are estimated to be from diarrheal diseases and pneumonia, and the use of these vaccines could potentially avert many of these deaths [19] .
In other countries with more stable health infrastructures, the issue of the cost-effectiveness of CHDs compared with investing in improving routine channels to deliver the same interventions has been raised. Analyses of other CHDs focus on the lack of integration with the primary healthcare system, such as separate reporting systems, different incentive schemes, and possible interruptions to routine service delivery [3] . In Somalia, where the health system is quite weak and virtually nonexistent in many areas, the CHDs probably do not encounter such pitfalls and may act to strengthen the routine healthcare delivery system by providing a large network of health workers the opportunity to learn about new interventions and how to deliver them. Eventually, steps should be taken to integrate CHDs into Somalia's healthcare delivery infrastructure, with the aim of using the most cost-effective service delivery strategy available. Somalia represents a unique fragile state with limited infrastructure, and caution is needed when extrapolating lessons and costs to other settings. Careful consideration of the context, including the available resources is required to identify the package of services delivered through CHDs in each context. Additional operational research is needed to further guide the choice of a country-specific package of services to be delivered through CHDs.
CONCLUSIONS
Our analysis indicates that with good planning and implementation, even countries in conflict can make progress toward the Millennium Development Goal to reduce child mortality in a cost-effective manner by delivering a package of child survival interventions using the CHD strategy. The 2 rounds of CHDs in Somalia meet the criteria for very cost-effective interventions and compare favorably with other health sector ''best buys'' in subSaharan Africa. Other countries in conflict that lack a routine health infrastructure could consider using the CHD strategy to deliver a package of child survival interventions that address the leading causes of child mortality. 
